{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06034002",
            "orgStudyIdInfo": {
                "id": "INCA33989-102"
            },
            "organization": {
                "fullName": "Incyte Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms",
            "officialTitle": "A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-administered-in-participants-with-myeloproliferative-neoplasms"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-10-29",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-10-29",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-30",
            "studyFirstSubmitQcDate": "2023-09-11",
            "studyFirstPostDateStruct": {
                "date": "2023-09-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Incyte Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms."
        },
        "conditionsModule": {
            "conditions": [
                "Myeloproliferative Neoplasms"
            ],
            "keywords": [
                "Myeloproliferative Neoplasms",
                "Myelofibrosis",
                "Essential thrombocythemia",
                "CALR mutation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1a Dose Escalation Cohort Disease Group A - with MF",
                    "type": "EXPERIMENTAL",
                    "description": "INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF) will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCA033989"
                    ]
                },
                {
                    "label": "Part 1a Dose Escalation Cohort Disease Group A - with ET",
                    "type": "EXPERIMENTAL",
                    "description": "INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with essential thrombocythemia (ET) will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCA033989"
                    ]
                },
                {
                    "label": "Part 1b: Dose Expansion - with MF",
                    "type": "EXPERIMENTAL",
                    "description": "INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCA033989"
                    ]
                },
                {
                    "label": "Part 1b: Dose Expansion - with ET",
                    "type": "EXPERIMENTAL",
                    "description": "INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCA033989"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INCA033989",
                    "description": "INCA033989 will be administered at protocol defined dose.",
                    "armGroupLabels": [
                        "Part 1a Dose Escalation Cohort Disease Group A - with ET",
                        "Part 1a Dose Escalation Cohort Disease Group A - with MF",
                        "Part 1b: Dose Expansion - with ET",
                        "Part 1b: Dose Expansion - with MF"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "description": "Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Number of participants with TEAEs leading to dose modification or discontinuation",
                    "description": "Number of participants with TEAEs leading to dose modification or discontinuation.",
                    "timeFrame": "Up to 3 years and 60 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Participants with MF: Response using the revised IWG-MRT and ELN response criteria for MF",
                    "description": "Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Participants With MF: Percentage of participants achieving spleen volume reduction as defined in the protocol",
                    "description": "Defined as percentage of participants with a protocol defined Spleen Volume Reduction.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Participants with MF with symptomatic anemia: Anemia Response",
                    "description": "For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Participants With ET: Response Rate",
                    "description": "Defined as the proportion of participants with Complete Response or Partial Response when treated with study drug.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Participants With ET: Mean change from baseline of total symptom score (TSS)",
                    "description": "Mean change of TSS from baseline.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Mean change in disease-related allele burden",
                    "description": "Mean change from baseline in disease-related variant allele frequency quantified by targeted NGS and evaluated with myeloid and lymphoid proportion in blood.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: Cmax of INCA33989",
                    "description": "Defined as maximum observed plasma concentration of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: Tmax of INCA033989",
                    "description": "Defined as the time to reach the maximum plasma concentration of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: Cmin of INCA33989",
                    "description": "Defined as the minimum observed plasma concentration of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: AUC(0-t) of INCA33989",
                    "description": "Defined as the area under the concentration-time curve up to the last measurable concentration of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: AUC 0-\u221e of INCA33989",
                    "description": "Defined as the area under the concentration-time curve from 0 to infinity of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: CL/F of INCA33989",
                    "description": "Defined as the apparent oral dose clearance of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: Vz/F of INCA33989",
                    "description": "Defined as the apparent oral dose volume of distribution of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                },
                {
                    "measure": "Pharmacokinetics Parameter: t1/2 of INCA33989",
                    "description": "Defined as the apparent terminal phase disposition half-life of INCA33989.",
                    "timeFrame": "Up to 3 years and 60 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Life expectancy \\> 6 months.\n* Willingness to undergo a pretreatment and regular on-study BM biopsies and aspirates (as appropriate to disease).\n* Existing documentation from a qualified local laboratory of CALR exon-9 mutation.\n* Participants with MF or ET as defined in the protocol.\n\nExclusion Criteria:\n\n* Presence of any hematological malignancy other than ET, PMF, or post-ET MF.\n* Prior history of major bleeding, or thrombosis within the last 3 months prior to study enrollment.\n* Participants with laboratory values exceeding the protocol defined thresholds.\n* Has undergone any prior allogenic or autologous stem-cell transplantation or such transplantation is planned.\n* Active invasive malignancy over the previous 2 years.\n* History of clinically significant or uncontrolled cardiac disease.\n* Active HBV/HCV or known history of HIV.\n* Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody, or hypomethylating agent used to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n* Participants undergoing treatment with G-CSF, GM-CSF, or TPO-R agonists at any time within 4 weeks before the first dose of study treatment.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Incyte Corporation Call Center (US)",
                    "role": "CONTACT",
                    "phone": "1.855.463.3463",
                    "email": "medinfo@incyte.com"
                },
                {
                    "name": "Incyte Corporation Call Center (ex-US)",
                    "role": "CONTACT",
                    "phone": "+800 00027423",
                    "email": "eumedinfo@incyte.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Incyte Medical Monitor",
                    "affiliation": "Incyte Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Stanford Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "University of Miami Health System",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "The University of Kansas Cancer Center",
                    "status": "RECRUITING",
                    "city": "Westwood",
                    "state": "Kansas",
                    "zip": "66205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.04056,
                        "lon": -94.6169
                    }
                },
                {
                    "facility": "Johns Hopkins Hospital",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Icahn School of Medicine At Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Wake Forest Baptist Medical Center",
                    "status": "RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27157",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Vanderbilt University Medical Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M16681",
                    "name": "Thrombocytosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M16679",
                    "name": "Thrombocythemia, Essential",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T2144",
                    "name": "Essential Thrombocythemia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}